Physician profile
Michelle L Devoll
NPI 1023520327
$9,560.90
in general payments reported to CMS, 2019-2025
60 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,739 · 2022: $1,942 · 2023: $1,850 · 2024: $2,007 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,880.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,312.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,113.41 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.82 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $447.62 | 2021-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $398.85 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $379.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.28 | 2022-2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $302.90 | 2022-2025 | Strensiq |
| Pfizer INC. | $301.70 | 2021-2025 | |
| Exact Sciences Corporation | $249.03 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $234.14 | 2021-2023 | Belsomra, Steglatro, Segluromet |
| Lundbeck LLC | $228.28 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $187.61 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $182.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $178.00 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Devoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.